circle

Investor & media center

Corporate Overview

PYC Therapeutics (ASX: PYC) is a development-stage biotechnology company pioneering a new generation of RNA therapeutics that utilize PYC’s proprietary library of naturally derived cell penetrating peptides to overcome the major challenges of current genetic medicines.

PYC believes its PPMO (Peptide conjugated Phosphorodiamidate Morpholino Oligomer) technology enables a safer and more effective RNA therapeutic to address the underlying drivers of a range of genetic diseases for which no treatment solutions exist today. The Company is leveraging its leading-edge science to develop a pipeline of novel therapies including three preclinical stage programs focused on inherited eye diseases and preclinical discovery efforts focused on neurodegenerative diseases.

PYC’s discovery and laboratory operations are located in Australia, and the Company’s preclinical, clinical, regulatory and corporate operations are based in San Diego, California.

Corporate Overview

Press Releases

2021

Retina Target Engagement Confirmed in Large Eye
28 Sep 2021 Download PDF
Upcoming Poster Presentations at TIDES USA and OTS 2021
21 Sep 2021 Download PDF
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
15 Sep 2021 Download PDF
Ophthalmology-Focused Clinical Advisory Board
17 Aug 2021 Download PDF
August Investor Update
17 Aug 2021 Download PDF
PYC Quarterly Investor Call – August 17
11 Aug 2021 Download PDF
August Investor Conferences
03 Aug 2021 Download PDF
Quarterly Activities/Appendix 4C Cash Flow Report
28 Jul 2021 Download PDF
Commencement of Larger Animal Studies for Lead Program
14 Jul 2021 Download PDF
Comprehensive Preclinical Results for VP-002 Program
29 Jun 2021 Download PDF
VP-002 Program – Technical Presentation
29 Jun 2021 Download PDF
New U.S. Headquarters, and Residency at Johnson & Johnson Innovation, JLABS
15 Jun 2021 Download PDF
Second Drug Program Progressing Towards Human Trials
08 Jun 2021 Download PDF
Evercore ISI GenomeRx Emerging Therapeutic Company Day
26 May 2021 Download PDF
Second Drug Program – Efficacy Data in Patient Cell Models
18 May 2021 Download PDF
PYC Invited to Present at ARVO 2021 Annual Meeting
04 May 2021 Download PDF
Set To Announce Efficacy Results For Second Drug Program
03 May 2021 Download PDF
March 2021 Quarterly Report and Cashflow
30 Apr 2021 Download PDF
April Investor Call Presentation
14 Apr 2021 Download PDF
Preclinical Data – Superior PPMO Delivery to the Brain
12 Apr 2021 Download PDF
Quarterly Investor Call – 15th April 2021
06 Apr 2021 Download PDF
PYC Appoints U.S. Biopharma Exec Jason Haddock to its Board
29 Mar 2021 Download PDF
Director Retirement
26 Mar 2021 Download PDF
Participation in SVB Leerink Biopharma Private Co Connect
22 Mar 2021 Download PDF
PYC Appoints US Biotech Veteran to its Board of Directors
17 Mar 2021 Download PDF
Lead Investigational Drug Demonstrates Key Improvement
02 Mar 2021 Download PDF
PYC Expands US Executive Leadership Team
23 Feb 2021 Download PDF
Progress US Clinical Stage Company and Corporate Objectives
22 Feb 2021 Download PDF
PYC to Participate in RNA Discussion – BIO CEO Conference
11 Feb 2021 Download PDF
December 2020 Quarterly Report and Cashflow
29 Jan 2021 Download PDF
ICR Conference Presentation
14 Jan 2021 Download PDF
PYC to Present at ICR Westwicke Conference
06 Jan 2021 Download PDF

2020

Visual Evidence of Lead Drugs Efficacy
16 Dec 2020 Download PDF
Letter to Shareholders from the US CEO
14 Dec 2020 Download PDF
Appointment of Chief Executive Officer in the United States
10 Dec 2020 Download PDF
PYC to Present at the Evercore ISI Conference
25 Nov 2020 Download PDF
Grants Awarded to Support Clinical Progression of Lead Drug
29 Oct 2020 Download PDF
FDA Response to Orphan Drug Designation Request
23 Oct 2020 Download PDF
Successful Institutional Entitlement Offer and Placement
22 Oct 2020 Download PDF
PYC Equity Raising to Raise Up to $55 Million
20 Oct 2020 Download PDF
New Drug for Substantial Unmet Need Added to Pipeline
12 Oct 2020 Download PDF
Investor Call 15th Oct 2020 12pm AEDT 9am AWST
09 Oct 2020 Download PDF
PYC’s Lead Drug Effective in Patient Derived Models Tested
07 Oct 2020 Download PDF
Second Potential Blockbuster Drug Added to PYC’s Pipeline
06 Oct 2020 Download PDF
Creation of Novel Gene Therapy Delivery Technology
08 Sep 2020 Download PDF
Executive Re-structure Across Global Operations
19 Aug 2020 Download PDF
Appointment of world-renowned Chief Scientific Officer
19 Aug 2020 Download PDF
Investor Call – 8am AWST – Wednesday 12 August 2020
03 Aug 2020 Download PDF
June 2020 Quarterly Activity Report and Cashflow
30 Jul 2020 Download PDF
Successful Dose Response & Toxicity Studies in Lead Program
22 Jul 2020 Download PDF
PYC Recruits High Profile Chief Medical Officer to US Ops
09 Jun 2020 Download PDF
World Class Results – Lions Eye Institute News Release
25 May 2020 Download PDF
March 2020 Quarterly Activities and Cash Flow Report
29 Apr 2020 Download PDF
Efficacy and Toxicity Studies Presentation
15 Apr 2020 Download PDF
Successful Toxicity Results Confirm Safety Advantage
08 Apr 2020 Download PDF
Investor Call 9.00am AWST Wed 1 April 2020
30 Mar 2020 Download PDF
NHMRC Grand for Identifying new Antisense Drugs
17 Feb 2020 Download PDF
CEO Appointment & Establishment of US Office
12 Feb 2020 Download PDF
Investor Call 27 February 2020
05 Feb 2020 Download PDF
Expansion of Drug Development Pipeline
03 Feb 2020 Download PDF
Quarterly Shareholder Update
06 Jan 2020 Download PDF

2019

Drug Delivery Greater than 100% more Effective – Amended
05 Dec 2019 Download PDF
Change in Substantial Holding
02 Dec 2019 Download PDF
Drug Delivery Greater than 100%
29 Nov 2019 Download PDF
Conclusion of Genentech Antimicrobial Collaboration
16 Nov 2019 Download PDF
PYC Increases Shareholding in Vision Pharma
14 Nov 2019 Download PDF
$26.8M Fully Underwritten accelerated Entitlement Offer
31 Oct 2019 Download PDF
Drug Delivery Greater than 100%
21 Oct 2019 Download PDF
Presentation Oligonucleotide Therapeutics Society Meeting
14 Oct 2019 Download PDF
Succesfful Major Milestone – Human Retina in a Dish Model
09 Oct 2019 Download PDF
Strategic Partnership and Lead Program
01 Oct 2019 Download PDF
Successful Time-Course Studies in Animals
25 Sep 2019 Download PDF
Scientific Advisory Board Appointment
13 Sep 2019 Download PDF
Successful Competitive Drug Evaluation in Animals
03 Sep 2019 Download PDF
Investor Call
23 Aug 2019 Download PDF
Successful Time – Course Studies in Animals
22 Aug 2019 Download PDF
Company Re-branding
09 Aug 2019 Download PDF
Phylogica’s Technology is Effective in Human Cells
06 Aug 2019 Download PDF
Operational Update and Appendix 4c
23 Jul 2019 Download PDF
Animal Models – 400% Outperformance of Gold Standard
23 Jul 2019 Download PDF
Break Through Animal Model Results
27 Jun 2019 Download PDF
March 2019 Quarterly Operational Update
29 Apr 2019 Download PDF
Scientific Advisory Board Appointment
22 Mar 2019 Download PDF

Events

Upcoming Events Past Events

Upcoming Events

More events are coming soon

Past Events

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

09/21/2021 View Event

Webinar: PYC Therapeutics & Genetic Signatures Morning Twilight Investor Briefing

09/16/2021 View Event

PYC Quarterly Investor Call

08/17/2021 View Event

H.C. Wainwright 2021 Virtual Ophthalmology Investor Conference

08/17/2021 View Event

Canaccord Genuity 41st Annual Growth Conference

08/12/2021 View Event

Wedbush PacGrow Healthcare Conference 2021

08/11/2021 View Event

Genetic Medicines Summit 2021

06/22/2021 View Event

PYC Quarterly Investor Call

04/15/2021 View Event

Turning RNA Research into Medicines Panel

02/17/2021 View Event

Webcast: PYC Therapeutics Limited

01/14/2021 View Event

Media Coverage

Filings and Governance

Annual Reports and Other ASX Filings Corporate Governance Charters Policies and Procedures

2021

NOTICE OF ANNUAL GENERAL MEETING 18TH NOVEMBER 2021
19 Oct 2021 Download PDF
Corporate Governance Statement and Appendix 4G
22 Sep 2021 Download PDF
Annual Report to Shareholders
22 Sep 2021 Download PDF
Preliminary Final Report
31 Aug 2021 Download PDF
Change of Auditor
01 Jul 2021 Download PDF
Exercise of Options
15 Jun 2021 Download PDF
Application for Quotation of Securities – PYC
15 Jun 2021 Download PDF
Trading Halt
07 Jun 2021 Download PDF
Appendix 3X – Initial Director’s Interest Notice
30 Mar 2021 Download PDF
Appendix 3G – Issue of Options
30 Mar 2021 Download PDF
Appendix 3G – Issue of Options
25 Mar 2021 Download PDF
Initial Director’s Interest Notice
23 Mar 2021 Download PDF
Half Year Accounts and Appendix 4D
26 Feb 2021 Download PDF
Change of Director’s Interest Notice
19 Feb 2021 Download PDF

2020

Initial Director’s Interest Notice
16 Dec 2020 Download PDF
Appendix 3G
16 Dec 2020 Download PDF
Change in substantial holding – Change in substantial holding
18 Nov 2020 Download PDF
Retail Entitlement Offer Share Issue and Appendix 2A
18 Nov 2020 Download PDF
Completion of Retail Entitlement Offer
13 Nov 2020 Download PDF
Final Director’s Interest Notice
10 Nov 2020 Download PDF
AGM Chairman’s Address and CEO Presentation
06 Nov 2020 Download PDF
Results of Annual General Meeting
06 Nov 2020 Download PDF
Change in Substantial Holding
28 Oct 2020 Download PDF
Change of Director’s Interest Notice x 2
28 Oct 2020 Download PDF
Notice under Section 708(A)
28 Oct 2020 Download PDF
Appendix 2A
27 Oct 2020 Download PDF
Dispatch of Retail Offer Document
26 Oct 2020 Download PDF
Dispatch of Notice to Ineligible Retail Shareholders
26 Oct 2020 Download PDF
Review of Activities and Appendix 4C
26 Oct 2020 Download PDF
Cleansing Notice Under Section 708AA
20 Oct 2020 Download PDF
Proposed Issue of Securities
20 Oct 2020 Download PDF
PYC Business and Equity Raising Presentation
20 Oct 2020 Download PDF
Trading Halt
16 Oct 2020 Download PDF
Completion of Retail Entitlement Offer
13 Oct 2020 Download PDF
9th October 2020 – Annual Report
09 Oct 2020 Download PDF
Technical Presentation – October 2020
09 Oct 2020 Download PDF
Notice of Directors intention not to seek re election at AGM
09 Oct 2020 Download PDF
Cancellation of Unlisted Options
09 Oct 2020 Download PDF
Notice of Annual General Meeting:Proxy Form
06 Oct 2020 Download PDF
Corporate Governance Statement and Appendix 4G
06 Oct 2020 Download PDF
Annual Report to shareholders
06 Oct 2020 Download PDF
Annual Financial Statements June 2020
14 Sep 2020 Download PDF
Appendix 4E Preliminary Final Report
31 Aug 2020 Download PDF
Shareholder Update August 2020
14 Aug 2020 Download PDF
Shareholder Update – Forward View 2020 Milestones
05 Aug 2020 Download PDF
Appendix 2A
09 Jul 2020 Download PDF
Appendix 3G
30 Jun 2020 Download PDF
Investor Presentation
22 Jun 2020 Download PDF
Change of Director’s Interest Notice x 2
16 Jun 2020 Download PDF
Change in substantial holding
16 Jun 2020 Download PDF
S&P DJI Announces June 2020 Quarterly Rebalance
12 Jun 2020 Download PDF
Appendix 3G
04 Jun 2020 Download PDF
Trading Halt
30 Mar 2020 Download PDF
Becoming a substantial holder
20 Mar 2020 Download PDF
Appendix 3G
18 Mar 2020 Download PDF
Half Yearly Report and Accounts
28 Feb 2020 Download PDF
Investor Presentation
24 Feb 2020 Download PDF
Appendix 3G
19 Feb 2020 Download PDF
Appendix 3G
18 Feb 2020 Download PDF
Appendix 3G
16 Feb 2020 Download PDF
Initial Director’s Interest Notice
12 Feb 2020 Download PDF
Appendix 4C – Quarterly
31 Jan 2020 Download PDF
Change of Share Registry
20 Jan 2020 Download PDF

2019

Quarterly Shareholder Update
06 Dec 2019 Download PDF
Change in Director’s Notice x 2
02 Dec 2019 Download PDF
Change in Substantial Holding_v2
02 Dec 2019 Download PDF
Ceasing to be a Substantial Holder
02 Dec 2019 Download PDF
Appendix 3B
28 Nov 2019 Download PDF
2019 AGM Chairman’s Address
27 Nov 2019 Download PDF
Change in Substantial Holding
27 Nov 2019 Download PDF
Results of 2019 Annual General Meeting
21 Nov 2019 Download PDF
2019 AGM Presentation
19 Nov 2019 Download PDF
Completion of Retail Entitlement Offer
19 Nov 2019 Download PDF
Change in Substantial Holding
12 Nov 2019 Download PDF
Change of Director’s Interest Notice
12 Nov 2019 Download PDF
Change in Substantial Holding
11 Nov 2019 Download PDF
Letter – Ineligible Shareholders
07 Nov 2019 Download PDF
Appendix 3B – Institutional offer
07 Nov 2019 Download PDF
PYC’s Institutional Entitlement Offer Closes
04 Nov 2019 Download PDF
Retail Offer Document
03 Nov 2019 Download PDF
Appendix 3B
31 Oct 2019 Download PDF
Entitlement Offer – Investor Presentation
31 Oct 2019 Download PDF
Notice Under Section 708AA
31 Oct 2019 Download PDF
Trading Halt
31 Oct 2019 Download PDF
Quarterly Shareholder Update and Appendix 4C
30 Oct 2019 Download PDF
Annual Report to Shareholders
18 Oct 2019 Download PDF
30th June 2019 Annual Report to Shareholders
18 Oct 2019 Download PDF
Appendix 4G
18 Oct 2019 Download PDF
Notice of Annual General Meeting : Proxy Form
18 Oct 2019 Download PDF
Investor Relations Presentation
15 Oct 2019 Download PDF
Trading Halt
30 Sep 2019 Download PDF
Full Year Statutory Accounts
17 Sep 2019 Download PDF
Investor Relations Presentation
04 Sep 2019 Download PDF
Preliminary Final Report
30 Aug 2019 Download PDF
Response to ASX Aware Query
07 Aug 2019 Download PDF
Company Presentation – July 2019
24 Jul 2019 Download PDF
Change of Director’s Interest Notice
24 Apr 2019 Download PDF

2018

30/06/2018 – Annual Report
30 Jun 2018 Download PDF

PYC Therapeutics Limited (“Company”) has adopted a Corporate Governance Plan which forms the basis of a comprehensive system of control and accountability for the administration of corporate governance.

The Board is committed to administering the policies and procedures with openness and integrity, pursuing the true spirit of corporate governance commensurate with the Company’s needs.

To the extent they are applicable to the Company, the Board has adopted the ASX Corporate Governance Council’s Corporate Governance Principles and Recommendations 3rd Edition (“Principles & Recommendations”).

A Corporate Governance Statement sets out details of the Company’s compliance with the Principles & Recommendations. Click here to read the ASX Corporate Governance Principles & Recommendations.

The Company is pleased to make the following information on its corporate governance practices available on this website.

CORPORATE GOVERNANCE STATEMENT
21 Sep 2021 Download PDF
CONSTITUTION – PYC THERAPEUTICS LIMITED
06 Nov 2020 Download PDF
RISK COMMITTEE
27 Jan 2021 Download PDF
REMUNERATION COMMITTEE
27 Jan 2021 Download PDF
NOMINATION COMMITTEE
27 Jan 2021 Download PDF
BOARD
27 Jan 2021 Download PDF
AUDIT COMMITTEE
27 Jan 2021 Download PDF
Anti-Bribery and Corruption Policy
21 Sep 2021 Download PDF
CORPORATE CODE OF CONDUCT
27 Jan 2021 Download PDF
DEFINITION OF INDEPENDENCE
27 Jan 2021 Download PDF
DISCLOSURE – CONTINUOUS DISCLOSURE
27 Jan 2021 Download PDF
DISCLOSURE – PERFORMANCE EVALUATION
27 Jan 2021 Download PDF
DISCLOSURE – RISK MANAGEMENT
27 Jan 2021 Download PDF
DIVERSITY POLICY
27 Jan 2021 Download PDF
SHAREHOLDER COMMUNICATION STRATEGY
27 Jan 2021 Download PDF
TRADING POLICY
27 Jan 2021 Download PDF
WHISTLEBLOWER POLICY
27 Jan 2021 Download PDF

Investor Relations and Media Contacts

Investors

Deborah Elson and Matthew DeYoung
Argot Partners
001.212.600.1902
deborah@argotpartners.com | matthew@argotpartners.com

Media

Leo Vartorella
Argot Partners
001.212.600.1902
leo@argotpartners.com

Discover more about our Pipeline

We are combining our proprietary CPP technology with world-leading expertise in PMO design to create a pipeline of highly precise, safe and effective combination drugs.

Our Pipeline